Navigation Links
Hard To Treat Diseases (HTDS) - CUSIP Change to Force Short Sellers To Cover
Date:9/15/2009

TORONTO, Sept. 15 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com The issuers received a certain e-mail after the market closed on September 14 2009 where amongst other things Pink Sheets claims that it has received complaints about improper promotions.

The company denies these allegations and finds these allegations disheartening and disingenuous in view of the fact that the issuer is subject to a naked short and has began a vigilant effort to have the shorts cover.

The company believes the short coverings started on September 14 as evidenced by the huge volume and over 100% raise in its share per price values in just a few short hours.

The issuer believes that a huge short position still exists on its security.

The sanctions of Pink Sheets will be namely placing a "Skull and Bones" icon and ranking on HTDS. The issuer will work vigorously to comply with Pink Sheets requests of filing a new Adequate Disclosure which according to Pink Sheets will remove the Skull and Bones rank.

The issuer has completed certain filings with Pink Sheets and an email exchange between both sides can be viewed on this link

http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=24223

HTDS and its advisors cannot and will not allow its security to be systematically erased off the books. Effective today Sept. 15, 2009 HTDS will request a new CUSIP number from its transfer agent. This "time out' which usually lasts 3-4 days to obtain the new CUSIP number will allow the company to prove to Pink Sheets that it had nothing to do with the improper "Promotion", and to complete the filings with Pink Sheets as per the Pink Sheets request see filing TAB or the direct link above.

More importantly, according to the rules, all broker dealers will have to reconcile their accounts and any short positions must be covered. This move by the HTDS management will also preserve the company equity and the last share price as recorded on close of September 14 2009.

During this 3-4 day "time out" the company will provide further updates and news so to assist shareholders with their positions and any short's not covered when the trading resumes. The issuer and its advisers feel that this is the most prudent and best course to take to protect its shareholders and its equity from the short seller's unscrupulous activities. The issuer apologizes for any inconvenience this has caused and assures its shareholders that the short term pain will be well worth the long term gain.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Particle Beam Radiation Therapy Promising But Unproven for Treating Cancer
2. Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
3. Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production
4. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
5. Study Shows Tubal Reversal Surgery is the Best Treatment to Have More Children After a Tubal Ligation
6. Drug Offers Hope Against Tough-to-Treat Hypertension
7. Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh
8. New Directions in Angioedema: A Focus on Supportive Care and Treatment Options
9. Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation, According to AIDS Treatment Activist Coalition Report Card
10. The American Legion Appeals to Congress for Compassionate Treatment of Women Veterans
11. Treating Childhood Leukemia With Fewer Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
Breaking Medicine Technology: